These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 19338042)

  • 1. Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Hwang YY; Tse E; So JC; Wan TS; Kwong YL
    Am J Hematol; 2009 May; 84(5):302-5. PubMed ID: 19338042
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CML: imatinib mesylate (Glivec) or something else?
    Ghosh A
    Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
    [No Abstract]   [Full Text] [Related]  

  • 4. Tyrosine kinase inhibitors for chronic myelogenous leukemia.
    Quintás-Cardama A; Kantarjian H; Cortes J
    N Engl J Med; 2007 Oct; 357(15):1557; author reply 1557-8. PubMed ID: 17933034
    [No Abstract]   [Full Text] [Related]  

  • 5. Applying the discovery of the Philadelphia chromosome.
    Sherbenou DW; Druker BJ
    J Clin Invest; 2007 Aug; 117(8):2067-74. PubMed ID: 17671641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trisomy 6 in a CML patient receiving imatinib mesylate therapy.
    Zámecníkova A; Al Bahar S; Ramesh P
    Leuk Res; 2008 Sep; 32(9):1454-7. PubMed ID: 18294688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
    Agarwal MB
    J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
    [No Abstract]   [Full Text] [Related]  

  • 8. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
    Tamura T; Tasaka T; Fujimoto M; Matsuhashi Y; Fukumot T; Mano S; Kuwajima M; Nagai M
    Haematologica; 2004 Sep; 89(9):ECR32. PubMed ID: 15377484
    [No Abstract]   [Full Text] [Related]  

  • 9. Chronic myelogenous leukemia progenitors display a genetically unstable personality.
    Rodrigues MS; Sattler M
    J Natl Cancer Inst; 2007 May; 99(9):662-3. PubMed ID: 17470729
    [No Abstract]   [Full Text] [Related]  

  • 10. Chronic myeloid leukemia with a novel four-way t(6;13;9;22)(p21;q32;q34;q11.2) successfully treated with imatinib mesylate.
    Kubota Y; Waki M
    Cancer Genet Cytogenet; 2010 Sep; 201(2):135-6. PubMed ID: 20682400
    [No Abstract]   [Full Text] [Related]  

  • 11. The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism.
    Breccia M; Alimena G
    Leuk Res; 2009 Jul; 33(7):871-5. PubMed ID: 19307018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib resistance in CML.
    Volpe G; Panuzzo C; Ulisciani S; Cilloni D
    Cancer Lett; 2009 Feb; 274(1):1-9. PubMed ID: 18653275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chronic myeloid leukemia and imatinib mesylate therapy].
    Chrobák L
    Vnitr Lek; 2004 Jan; 50(1):10-2. PubMed ID: 15015223
    [No Abstract]   [Full Text] [Related]  

  • 14. Managing relapse of CML using therapeutic imatinib plasma level.
    Onitilo AA; Engel JM
    Clin Adv Hematol Oncol; 2009 Nov; 7(11):763-7. PubMed ID: 20075835
    [No Abstract]   [Full Text] [Related]  

  • 15. Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?
    Maziarz RT
    Curr Opin Hematol; 2008 Mar; 15(2):127-33. PubMed ID: 18300759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: a disease or a drug effect?
    Ram R; Gafter-Gvili A; Okon E; Pazgal I; Shpilberg O; Raanani P
    Acta Haematol; 2008; 119(2):104-7. PubMed ID: 18367829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resolution of rheumatoid arthritis symptoms with imatinib mesylate.
    Vernon MR; Pearson L; Atallah E
    J Clin Rheumatol; 2009 Aug; 15(5):267. PubMed ID: 19654496
    [No Abstract]   [Full Text] [Related]  

  • 18. Bone marrow with gelatinous transformation associated with residual disease in imatinib mesylate-treated chronic myelogenous leukaemia (CML).
    Thakral B; Higa B; Venkataraman G; Velankar MM
    Pathology; 2012 Jan; 44(1):59. PubMed ID: 22157697
    [No Abstract]   [Full Text] [Related]  

  • 19. Imatinib and regression of type 2 diabetes.
    Veneri D; Franchini M; Bonora E
    N Engl J Med; 2005 Mar; 352(10):1049-50. PubMed ID: 15758023
    [No Abstract]   [Full Text] [Related]  

  • 20. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
    Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M
    Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.